文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 高等教育 > 医学 > Validation of structural and functional lesions of diabetic
侵权投诉

Validation of structural and functional lesions of diabetic

Validation of structural and functional lesions of diabetic

Molecular Vision 2010; 16:2121-2131 <doc.guandang.net 16 March 2010 | Accepted 14 October 2010 | Published 19 October 2010

© 2010 Molecular Vision

Validation of structural and functional lesions of diabeticretinopathy in mice

T.S. Kern,1,2 J. Tang,1 B.A. Berkowitz3

1Case Western Reserve University, Cleveland, OH; 2Veterans Affairs Medical Center, Cleveland, OH; 3Wayne State University,

Detroit, MI

Diabetic retinopathy is a serious long-term complication of diabetes mellitus. There is considerable interest in using mousemodels, which can be genetically modified, to understand how retinopathy develops and can be inhibited. Not all retinallesions that develop in diabetic patients have been reproduced in diabetic mice; conversely, not all abnormalities foundin diabetic mice have been studied or identified in diabetic patients. Thus, it is important to recognize which structuraland functional abnormalities that develop in diabetic mice have been validated against the lesions that characteristicallydevelop in diabetic patients. Those lesions that have been observed to develop in the mouse models to date arepredominantly characteristic of the early stages of retinopathy. Identification of new therapeutic ways to inhibit these earlylesions is expected to help inhibit progression to more advanced and clinically important stages of retinopathy.

Studies in diabetic animals have provided valuableinsight into the pathogenesis of diabetic retinopathy (DR). Forexample, studies of diabetic dogs demonstrated that improvedglycemic control could inhibit the development of theretinopathy more than 16 years before a comparabledemonstration in diabetic patients [1]. The possibility ofgenetic manipulation, and the availability of reagents andantibodies for molecular studies, has led to great interest insmaller species such as the mouse for studies of DR. Inaddition, the development of noninvasive, translationalimaging methods that can be applied to both humans andanimals has opened new opportunities for investigating thepathophysiology of DR. Several laboratory species have beencompared with regard to which retinal lesions develop indiabetes, with the general conclusion that more types oflesions develop in larger, longer-lived models (primates,dogs) than in smaller, shorter-lived models (rats, mice) [2].

At present, a range of anatomic and functional retinallesions linked with DR have been identified by a variety ofmethods. The identification of the lesions that are most criticalto this retinopathy, as well as the methods that bestdemonstrate these abnormalities, has been controversial. Inthe present text, “robust” lesions are defined as those thatoccur in both human and mouse models, and have beenidentified by different laboratories, independent of themethods used. This category does not rule out the possibilitythat other retinal lesions represent real and important damageinflicted on the retina by diabetes, but indicates only that

Correspondence to: Timothy S. Kern, Clinical and MolecularEndocrinology, Department of Medicine, 434 Biomedical ResearchBuilding, Case Western Reserve University, 10900 Euclid Ave.,Cleveland, OH, 44106-4951; Phone: (216) 368-0800; FAX: (216)368-5824; email: tsk@case.edu

important inconsistencies and/or questions remain in theliterature. To aid future efforts at translational studies, in thisreview, we will emphasize existing anatomic and physiologiclesions that fit this classification.

1. DIABETIC RETINOPATHY IN HUMANS

DR is a common complication of diabetes, and one of theleading causes of visual loss in working age populations indeveloped countries. It has been found to affect the majorityof patients who have had diabetes for 1–2 decades, althoughnot all patients develop a comparable severity of retinaldisease. The major risk factors of DR are the degree andduration of hyperglycemia. The retinal lesions that develop intype 1 diabetes are not different from those that develop intype 2 diabetes, although the severity and/or incidence of thelesions may differ. For example, the severity of retinal edemaand neovascularization differ between different types ofdiabetes [3].

1A. Characteristic structural changes.

1A1. Vascular pathology—Clinically detectablecharacteristics of DR have focused on damage to the retinalvasculature. Based on vascular changes, DR is subdivided intoan early nonproliferative stage including progressive capillaryocclusion and degeneration (NPDR), and a more advanced,proliferative or neovascular stage (PDR) [4]. In addition,macular edema (i.e., retinal edema involving or threateningthe macula) can occur in both stages, can be diffuse or focalin distribution, and can have a cystoid appearance or not.

Other vascular lesions of NPDR include the appearanceof microaneurysms, vascular nonperfusion, and degeneration(Figure 1). Capillary degeneration and nonperfusion aretightly associated, but it remains unclear if they occurindependently of each other, or if one always causes the other.

Validation of structural and functional lesions of diabetic

Nonetheless, degenerate capillaries are very important lesions

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email